Lead sponsor
Fudan University
6 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
6
Trials led
3
Active
17,553
Total enrollment
6
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2/3
1
Phase 4
1
Not applicable
4
Trials by status
Not yet recruiting
3
Completed
2
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention—not applicableNot yet recruiting16,509
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention—not applicableNot yet recruiting460
Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility ScoresHbA1c ≤9%not applicableNot yet recruiting418
Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 DiabetesBMI ≥24Ph 4Completed76
Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide—not applicableUnknown60